Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 9, 2025, details a material definitive agreement entered into by Citius Pharmaceuticals, Inc. The company, incorporated in Nevada and trading on the Nasdaq Capital Market, announced a registered direct offering that closed on June 11, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6.0 million.
- Net Proceeds: Approximately $5,455,000 after deducting placement agent fees and offering expenses.
- Securities Issued:
- 540,000 shares of common stock at $1.22 per share.
- Pre-funded warrants to purchase up to 4,380,000 shares at $1.2199 per share.
- Warrants to purchase up to 9,840,000 shares at an exercise price of $1.00 per share.
- Placement Agent Fees: 7.0% of gross proceeds paid to H.C. Wainwright and Co., LLC, plus reimbursement for legal and other expenses totaling approximately $100,950.
- Placement Agent Warrants: 344,400 warrants issued to the agent with an exercise price of $1.525 per share.
Material Changes and Use of Proceeds
The primary material change is the increase in equity capital and potential dilution from the issuance of shares and warrants. The company anticipates using the net proceeds to support the commercial launch of its product LYMPHIR™, including milestone, regulatory, and other payments, as well as general corporate purposes.
Outlook, Risks, and Covenants
- Lock-Up Period: The company agreed not to issue or announce the issuance of common stock or convertible securities for 60 days following the closing, with an exception for "at the market" offerings after 30 days at a price of $1.75 or greater per share.
- Warrant Terms: Investor warrants are exercisable immediately and expire 24 months after the initial exercise date. They include a beneficial ownership limitation of 4.99% (electable up to 9.99%).
- Risks: The transaction involves significant dilution to existing shareholders due to the issuance of common stock and a large number of warrants. The company's ability to execute the commercial launch of LYMPHIR™ depends on the successful deployment of these funds.
Key Facts for Investor Verification
- Verify the exact closing date of the offering (June 11, 2025) and the final net proceeds received.
- Confirm the total number of shares outstanding post-offering to assess the dilution impact of the 540,000 shares and 14,220,000 warrant shares.
- Review the specific milestones and regulatory payments associated with the LYMPHIR™ launch to understand the burn rate of the $5.455 million net proceeds.
- Monitor the company's compliance with the 60-day lock-up period and the conditions for the "at the market" offering exception.